Genpharmasec Rights Issue 2024 FAQ's

₹48.45 Crores | Listing at BSE | Tue, Jan 23, 2024 - Tue, Feb 13, 2024

Genpharmasec Limited Rights Issue Date 2026 & Price FAQs

The timetable for Genpharmasec Limited Rights Issue is as follows:

Last Date for credit of Rights Entitlements
Last Date for renunciation of Rights EntitlementsFri, Feb 2, 2024
Issue Opening DateTue, Jan 23, 2024
Issue Closing DateTue, Feb 13, 2024
Date of Allotment (on or about)Fri, Feb 16, 2024
Date of Credit (on or about)Wed, Feb 21, 2024
Date of Listing (on or about)Mon, Feb 26, 2024

Genpharmasec Rights Issue 2024 price is set at ₹1.75 per share. The Genpharmasec Rights Issue 2024 opens on Tue, Jan 23, 2024, and closes on Tue, Feb 13, 2024, for the subscription.

The allotment of Genpharmasec Rights Issue 2024 is expected to happen on or about February 16, 2024 as per the issue schedule.

Genpharmasec Rights Issue 2024 is expected to list on or around February 26, 2024.

The credit of Genpharmasec Rights Issue 2024 in Demat account is expected on or about February 21, 2024 as per the issue schedule.

Objects of the Issue:

The company proposes to utilize the net proceeds from the Issue towards funding the following objects:

  1. To acquire Equity Shares from existing shareholders of Derren Healthcare Private Limited and make it a subsidiary Company
  2. To repay or prepay, in full or in part, certain Borrowings availed by our Company.
  3. To part finance the requirement of Working Capital;
  4. To meet General corporate purposes;
  5. To meet the expenses of the Issue.

It is difficult to predict the exact listing price of Genpharmasec Limited Rights Issue shares. The price depends on the demand and supply of the company's shares on the day of listing.

We do not provide Rights Issue recommendations. However, we share a lot of information about Genpharmasec Limited which could help you with questions like whether to subscribe or not. Consider reading Genpharmasec Limited reviews and analysis from experts posted on the Rights Issue detail page.